Format
Sort by

Send to

Choose Destination

Links from Books

Items: 16

1.

Imaging of tumor angiogenesis using 99mTc-labeled human recombinant anti-ED-B fibronectin antibody fragments.

Berndorff D, Borkowski S, Moosmayer D, Viti F, Müller-Tiemann B, Sieger S, Friebe M, Hilger CS, Zardi L, Neri D, Dinkelborg LM.

J Nucl Med. 2006 Oct;47(10):1707-16.

2.

Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.

Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D.

Curr Med Chem. 2006;13(16):1845-57. Review.

PMID:
16842197
3.

Positron emission tomographic imaging of angiogenesis and vascular function.

Laking GR, Price PM.

Br J Radiol. 2003;76 Spec No 1:S50-9. Review.

PMID:
15456714
4.

[Tc(CO)(3)](+) chemistry: a promising new concept for SPET? For.

Alberto R.

Eur J Nucl Med Mol Imaging. 2003 Sep;30(9):1299-302. Epub 2003 Jul 29. No abstract available.

PMID:
12898204
5.

Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.

Shinkaruk S, Bayle M, Laïn G, Déléris G.

Curr Med Chem Anticancer Agents. 2003 Mar;3(2):95-117. Review.

PMID:
12678905
6.

Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer.

Santimaria M, Moscatelli G, Viale GL, Giovannoni L, Neri G, Viti F, Leprini A, Borsi L, Castellani P, Zardi L, Neri D, Riva P.

Clin Cancer Res. 2003 Feb;9(2):571-9.

7.

Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin.

Borsi L, Balza E, Bestagno M, Castellani P, Carnemolla B, Biro A, Leprini A, Sepulveda J, Burrone O, Neri D, Zardi L.

Int J Cancer. 2002 Nov 1;102(1):75-85.

8.

Synthesis and properties of boranocarbonate: a convenient in situ CO source for the aqueous preparation of [(99m)Tc(OH(2))3(CO)3]+.

Alberto R, Ortner K, Wheatley N, Schibli R, Schubiger AP.

J Am Chem Soc. 2001 Apr 4;123(13):3135-6. No abstract available.

PMID:
11457025
9.

A high-affinity human antibody that targets tumoral blood vessels.

Tarli L, Balza E, Viti F, Borsi L, Castellani P, Berndorff D, Dinkelborg L, Neri D, Zardi L.

Blood. 1999 Jul 1;94(1):192-8.

10.

Comparison of the stability of technetium-labeled peptides to challenge with cysteine.

Stalteri MA, Bansal S, Hider R, Mather SJ.

Bioconjug Chem. 1999 Jan-Feb;10(1):130-6.

PMID:
9893974
11.

Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel.

Pini A, Viti F, Santucci A, Carnemolla B, Zardi L, Neri P, Neri D.

J Biol Chem. 1998 Aug 21;273(34):21769-76.

12.

Molecular variants of fibronectin and laminin: structure, physiological occurrence and histopathological aspects.

Kosmehl H, Berndt A, Katenkamp D.

Virchows Arch. 1996 Dec;429(6):311-22. Review.

PMID:
8982375
13.
14.

Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues.

Kaczmarek J, Castellani P, Nicolo G, Spina B, Allemanni G, Zardi L.

Int J Cancer. 1994 Oct 1;59(1):11-6.

PMID:
7927891
15.

The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis.

Castellani P, Viale G, Dorcaratto A, Nicolo G, Kaczmarek J, Querze G, Zardi L.

Int J Cancer. 1994 Dec 1;59(5):612-8. Erratum in: Int J Cancer 1995 Jul 4;62(1):118.

PMID:
7525495
16.

A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors.

Carnemolla B, Balza E, Siri A, Zardi L, Nicotra MR, Bigotti A, Natali PG.

J Cell Biol. 1989 Mar;108(3):1139-48.

Items per page

Supplemental Content

Write to the Help Desk